Antiviral use is associated with a decrease in the rate of influenza-related complications, health care resource utilization, and costs

References

• World Health Organization. Fact sheet: influenza (Seasonal); 2020. [cited 2020 March 22]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal)
   Google Scholar
• Garten R, Blanton L, Elal AIA, et al. Update: influenza activity in the United States during the 2017-18 season and composition of the 2018-19 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2018;67(22):634–642.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. FluView: laboratory-confirmed influenza hospitalizations; 2020. [cited 2020 March 22]. Available from: https://gis.cdc.gov/grasp/fluview/fluhosprates.html
   Google Scholar
• GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2019;7(1):69–89.
   PubMed Web of Science ®Google Scholar
• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–1300.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. People at high risk of developing serious flu-related complications. 2018. [cited 2020 March 22]. Available from: https://www.cdc.gov/flu/about/disease/high_risk.htm
   Google Scholar
• Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061.
   PubMed Web of Science ®Google Scholar
• Putri W, Muscatello DJ, Stockwell MS, et al. Economic burden of seasonal influenza in the United States. Vaccine. 2018;36(27):3960–3966.
   PubMed Web of Science ®Google Scholar
• Yan S, Weycker D, Sokolowski S. US healthcare costs attributable to type A and type B influenza. Hum Vaccin Immunother. 2017;13(9):2041–2047.
   PubMed Web of Science ®Google Scholar
• Lu PJ, Singleton JA, Euler GL, et al. Seasonal influenza vaccination coverage among adult populations in the United States, 2005–2011. Am J Epidemiol. 2013;178(9):1478–1487.
   PubMed Web of Science ®Google Scholar
• Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):e1–e47.
   PubMed Web of Science ®Google Scholar
• Heneghan CJ, Onakpoya I, Jones MA, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess. 2016;20(42):1–242.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014; 4:CD008965.
   PubMed Web of Science ®Google Scholar
• Burch J, Paulden M, Conti S, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess. 2009;13(58):1–265.
   PubMed Web of Science ®Google Scholar
• Muthuri SG, Venkatesan S, Myles PR, et al. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. Influenza Other Respir Viruses. 2016;10(3):192–204.
   PubMed Web of Science ®Google Scholar
• Doll MK, Winters N, Boikos C, et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017;72(11):2990–3007.
   PubMed Web of Science ®Google Scholar
• Spagnuolo PJ, Zhang M, Xu Y, et al. Effects of antiviral treatment on influenza-related complications over four influenza seasons: 2006-2010. Curr Med Res Opin. 2016;32(8):1399–1407.
   PubMed Web of Science ®Google Scholar
• Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis. 2011;53(3):277–279.
   PubMed Web of Science ®Google Scholar
• Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163(14):1667–1672.
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326(7401):1235.
   PubMed Web of Science ®Google Scholar
• Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385(9979):1729–1737.
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2018–2019 Influenza Season. MMWR Recomm Rep. 2018;67(3):1–20.
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. Measuring price change in the CPI: medical care; 2020. [cited 2020 November 24]. Available from: https://www.bls.gov/cpi/factsheets/medical-care.htm.
   Google Scholar
• Centers for Disease Control and Prevention. Background document for "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018-19 Influenza Season”. August 23, 2018. [cited 2020 March 22]. Available from: https://www.cdc.gov/vaccines/acip/index.html.
   Google Scholar
• Tokars JI, Olsen SJ, Reed C. Seasonal incidence of symptomatic influenza in the United States. Clin Infect Dis. 2018;66(10):1511–1518.
   PubMed Web of Science ®Google Scholar
• Wallick C, To TM, Korom S, et al. Impact of influenza on the short- and long-term health of patients with chronic obstructive pulmonary disease. Poster session presented at: 6th International Society for Influenza and other Respiratory Virus Diseases (ISIRV)-Antiviral Group (AVG) conference. Nov 13–15; Rockville, MD: 2018.
   Google Scholar
• Lipsitch M, Hernan MA. Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants. Clin Infect Dis. 2013;57(9):1368–1369.
   PubMed Web of Science ®Google Scholar
• Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study. Curr Med Res Opin. 2007;23(12):2961–2970.
   PubMed Web of Science ®Google Scholar
• Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics. 2009;124(1):170–178.
   PubMed Web of Science ®Google Scholar
• Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother. 2008;9(2):151–161.
   PubMed Web of Science ®Google Scholar
• Keren R, Wheeler A, Coffin SE, et al. ICD-9 codes for identifying influenza hospitalizations in children. Emerg Infect Dis. 2006;12(10):1603–1604.
   PubMed Web of Science ®Google Scholar
• Feemster KA, Leckerman KH, Middleton M, et al. Use of administrative data for the identification of laboratory-confirmed influenza infection: the validity of influenza-specific ICD-9 codes. J Pediatric Infect Dis Soc. 2013;2(1):63–66.
   PubMedGoogle Scholar
• Amodio E, Tramuto F, Costantino C, et al. Diagnosis of influenza: only a problem of coding? Med Princ Pract. 2014;23(6):568–573.
   PubMed Web of Science ®Google Scholar